Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0

作者：

Linton, Kim M. ^{[1
,2
]}

Wahlin, Bjorn ^{[3
,4
]}

Leppa, Sirpa ^{[5
]}

Morschhauser, Franck ^{[6
]}

Elliott, Brian ^{[7
]}

Liu, Tracy ^{[7
]}

Stirner, Mariana Cota ^{[8
]}

Abbas, Aqeel ^{[7
]}

Falchi, Lorenzo ^{[9
]}

机构：

[1] Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Manchester Canc Res Ctr, Manchester, Lancs, England

[3] Karolinska Inst, Stockholm, Sweden

[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[5] Univ Helsinki, Helsinki, Finland

[6] Univ Lille, CHU Lille, Lille, France

[7] Genmab, Princeton, NJ USA

[8] AbbVie, N Chicago, IL 60064 USA

[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH22-PO53

引用

页码：94 / 94

页数：1

共 50 条

[41] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA [J].

Dutia, M. ;

DeRoock, I. ;

Chee, K. ;

O'Donnell, R. ;

Quirch, C. ;

Reed-Pease, C. ;

Tuscano, J. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 :118-118

[42] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) [J].

Sehn, Laurie H. ;

Hubel, Kai ;

Luminari, Stefano ;

Salar, Antonio ;

Wahlin, Bjorn E. ;

Gopal, Ajay K. ;

Bonnet, Christophe ;

Paneesha, Shankara ;

Trneny, Marek ;

Mashegu, Hafsat ;

Lihou, Christine F. ;

Cheng, Lulu ;

Scholz, Christian W. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S385-S386

[43] Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphoma [J].

Wang, M. ;

Fayad, L. ;

Hagemeister, F. ;

Neelapu, S. ;

Samuels, B. ;

Samanigo, F. ;

Pro, B. ;

Yi, Q. ;

Bell, N. ;

Byrne, C. ;

Weaver, P. ;

Hartig, K. ;

Knight, R. ;

Zeldis, J. ;

Kwak, L. ;

Romaguera, J. .

ANNALS OF ONCOLOGY, 2008, 19 :174-174

[44] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS [J].

Burke, J. M. ;

Andorsky, D. J. ;

Yacoub, A. ;

Melear, J. ;

Coleman, M. ;

Kolibaba, K. ;

Brooks, H. ;

Bitran, J. ;

Fanning, S. ;

Lansigan, F. ;

Ricker, J. L. ;

Foon, K. ;

Llorente, M. ;

Li, J. ;

Sharman, J. .

HAEMATOLOGICA, 2017, 102 :249-250

[45] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial [J].

Kersten, Marie Jose ;

Dreyling, Martin ;

Linton, Kim M. ;

Chitu, Dana ;

Tonino, Sanne ;

Kap, Marcel ;

Liu, Roberto D. ;

Chamuleau, Martine E. D. ;

Visser, Hein P. J. ;

De Jongh, Eva ;

Marijt, Erik Waf ;

Leijs, Maria B. L. ;

Bilgin, Yavuz M. ;

Duerig, Jan ;

McKay, Pamela ;

Snijders, Tjeerd J. F. ;

Pettitt, Andrew ;

Minnema, Monique C. ;

Prange-Krex, Gabriele ;

Cuijpers, Maria ;

Boehmer, Lara H. ;

Tick, Lidwine W. ;

Florschuetz, Axel ;

Silbermann, Matthijs ;

Fijnheer, Rob ;

Beeker, Aart ;

Tolboom, Nelleke ;

Mitea, Cristina ;

Arens, Anne I. J. ;

Zwezerijnen, Gerben J. C. ;

Klapper, Wolfram ;

Coupland, Sarah E. ;

de Jong, Daphne ;

Doorduijn, Jeanette K. ;

Zijlstra, Josee M. .

BLOOD, 2022, 140 :2283-2285

[46] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia [J].

Chavez, Julio C. ;

Piris-Villaespesa, Miguel ;

Dalia, Samir ;

Powers, John ;

Turba, Elyce ;

Nodzon, Lisa ;

Komrokji, Rami ;

Sokol, Lubomir ;

Locke, Frederick L. ;

Lancet, Jeffrey ;

Sotomayor, Eduardo M. ;

Kharfan-Dabaja, Mohamed A. ;

Pinilla-Ibarz, Javier .

LEUKEMIA RESEARCH, 2016, 47 :78-83

[47] Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma [J].

Rubenstein, James L. ;

Geng, Huimin ;

Fraser, Eleanor J. ;

Formaker, Paul ;

Chen, Lingjing ;

Sharma, Jigyasa ;

Killea, Phoebe ;

Choi, Kaylee ;

Ventura, Jenny ;

Kurhanewicz, John ;

Lowell, Clifford ;

Hwang, Jimmy ;

Treseler, Patrick ;

Sneed, Penny K. ;

Li, Jing ;

Wang, Xiaomin ;

Chen, Nianhang ;

Gangoiti, Jon ;

Munster, Pamela N. ;

Damato, Bertil .

BLOOD ADVANCES, 2018, 2 (13) :1595-1607

[48] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma [J].

Herrera, Alex F. ;

Bartlett, Nancy L. ;

Ramchandren, Radhakrishnan ;

Vose, Julie M. ;

Moskowitz, Alison J. ;

Feldman, Tatyana A. ;

LaCasce, Ann S. ;

Ansell, Stephen M. ;

Moskowitz, Craig H. ;

Fenton, Keenan ;

Kato, Kazunobu ;

Fong, Abraham ;

Advani, Ranjana H. .

BLOOD, 2016, 128 (22)

[49] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma [J].

Dhillon, Sohita .

TARGETED ONCOLOGY, 2017, 12 (02) :255-262

[50] Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial [J].

Kater, Arnon P. ;

Christensen, Jacob Haaber ;

Bentzen, Hans Herluf ;

Niemann, Carsten Utoft ;

Hutchings, Martin ;

Chen, Jenny ;

Rios, Marcia ;

Palenski, Tammy ;

Li, Tommy ;

Mato, Anthony R. .

BLOOD, 2021, 138

← 1 2 3 4 5 →